RNS Number : 2225B
BSF Enterprise PLC
01 June 2023

1 June 2023

BSF Enterprise PLC
("BSF" or the "Company")

Publication of New Research

BSF (LSE: BSFA; OTCQB: BSFAF), the Main Market listed biotech company and the owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to inform shareholders that a new research note on the Company has recently been published by Shard Capital Partners LLP.

The note can be found on the Company's website, www.bsfenterprise.com, or via the Shard Portal.

-Ends-

For further enquiries, please visit www.bsfenterprise.com or contact:

BSF Enterprise PLC
Che Connon - CEO & Executive Director
Geoff Baker - Executive Director
Via SEC Newgate below

Shard Capital (Broker)
Damon Heath
Isabella Pierre
0203 971 7000
0207 1869 927

SEC Newgate (Financial Communications)
Bob Huxford
Elisabeth Cowell
George Esmond
020 3757 6882
BSF@secnewgate.co.uk

ISIN of the Ordinary Shares is GB00BHNBDQ51
SEDOL Code is BHNBDQ5.

Notes to Editors
BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it has produced the UK's first high quality lab-grown meat from its laboratory using its technology.

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as acquiring complementary businesses. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DOCEFLFXXELFBBV